Top

Published in:

01-09-2008 | how i do it

How I Do It: Surgical Management of Gastrointestinal Stromal Tumors

Authors: Chandrajit P. Raut, Stanley W. Ashley

Published in: Journal of Gastrointestinal Surgery | Issue 9/2008

Abstract

The surgical management of gastrointestinal stromal tumors (GISTs) has been impacted by the development of tyrosine kinase inhibitors (TKIs), advances in surgical technique, and a better understanding of the natural history of this unique disease. In this article, we review the technical aspects of the operations, the expanding role of laparoscopy, and the indications for neoadjuvant and neoadjuvant TKI therapy in primary GIST. Furthermore, we explore the rationale for and incorporation of surgery in the multidisciplinary management of advanced GIST.

Gayed I, Vu T, Iyer R, et al. The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors. J Nucl Med 2004;45(1):17–21.PubMed

Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol 2006;23(2):70–83.PubMedCrossRef

Fujimoto Y, Nakanishi Y, Yoshimura K, Shimoda T. Clinicopathologic study of primary malignant gastrointestinal stromal tumor of the stomach, with special reference to prognostic factors: analysis of results in 140 surgically resected patients. Gastric Cancer 2003;6(1):39–48.PubMedCrossRef

Otani Y, Furukawa T, Yoshida M, et al. Operative indications for relatively small (2–5 cm) gastrointestinal stromal tumor of the stomach based on analysis of 60 operated cases. Surgery 2006;139(4):484–492.PubMedCrossRef

Novitsky YW, Kercher KW, Sing RF, Heniford BT. Long-term outcomes of laparoscopic resection of gastric gastrointestinal stromal tumors. Ann Surg 2006;243(6):738–45. discussion 745–747.PubMedCrossRef

Agaimy A, Wunsch PH, Hofstaedter F, et al. Minute gastric sclerosing stromal tumors (GIST tumorlets) are common in adults and frequently show c-KIT mutations. Am J Surg Pathol 2007;31(1):113–120.PubMedCrossRef

Kawanowa K, Sakuma Y, Sakurai S, et al. High incidence of microscopic gastrointestinal stromal tumors in the stomach. Hum Pathol 2006;37(12):1527–1535.PubMedCrossRef

Davila RE, Faigel DO. GI stromal tumors. Gastrointest Endosc 2003;58(1):80–88.PubMedCrossRef

Heinrich MC, Corless CL. Gastric GI stromal tumors (GISTs): the role of surgery in the era of targeted therapy. J Surg Oncol 2005;90(3):195–207. discussion 207.PubMedCrossRef

10.

Demetri GD, Benjamin RS, Blanke CD, et al. NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)—update of the NCCN clinical practice guidelines. J Natl Compr Canc Netw 2007;5(Suppl 2):S1–29. quiz S30.PubMed

11.

Crosby JA, Catton CN, Davis A, et al. Malignant gastrointestinal stromal tumors of the small intestine: a review of 50 cases from a prospective database. Ann Surg Oncol 2001;8(1):50–59.PubMedCrossRef

12.

DeMatteo RP, Lewis JJ, Leung D, et al. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 2000;231(1):51–58.PubMedCrossRef

13.

Pierie JP, Choudry U, Muzikansky A, et al. The effect of surgery and grade on outcome of gastrointestinal stromal tumors. Arch Surg 2001;136(4):383–389.PubMedCrossRef

14.

DeMatteo R, Owzar K, Maki R, et al. Adjuvant imatinib mesylate increases recurrence free survival (RFS) in patients with completely localized primary gastrointestinal stromal tumor (GIST): North American Intergroup Phase III trial ACOSOG Z9001. Proc Am Soc Clin Oncol 2007:Abstract No 10079.

15.

Bauer S, Hartmann JT, de Wit M, et al. Resection of residual disease in patients with metastatic gastrointestinal stromal tumors responding to treatment with imatinib. Int J Cancer 2005;117(2):316–325.PubMedCrossRef

16.

Scaife CL, Hunt KK, Patel SR, et al. Is there a role for surgery in patients with “unresectable” cKIT + gastrointestinal stromal tumors treated with imatinib mesylate. Am J Surg 2003;186(6):665–669.PubMedCrossRef

17.

Verweij J, Casali PG, Zalcberg J, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004;364(9440):1127–1134.PubMedCrossRef

18.

DeMatteo RP, Maki RG, Singer S, et al. Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor. Ann Surg 2007;245(3):347–352.PubMedCrossRef

19.

Raut CP, Posner M, Desai J, et al. Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. J Clin Oncol 2006;24(15):2325–2331.PubMedCrossRef

20.

Heinrich MC, Corless CL, Liegl B, et al. Mechanisms of sunitinib malate resistance in gastrointestinal stromal tumors. Proc Am Soc Clin Oncol 2007;25(18S):10006. (Abst).

21.

Andtbacka RH, Ng CS, Scaife CL, et al. Surgical resection of gastrointestinal stromal tumors after treatment with imatinib. Ann Surg Oncol 2007;14:14–24.PubMedCrossRef

22.

Bonvalot S, Eldweny H, Pechoux CL, et al. Impact of surgery on advanced gastrointestinal stromal tumors (GIST) in the imatinib era. Ann Surg Oncol 2006;13(12):1596–1603.PubMedCrossRef

23.

Gronchi A, Fiore M, Miselli F, et al. Surgery of residual disease following molecular-targeted therapy with imatinib mesylate in advanced/metastatic GIST. Ann Surg 2007;245(3):341–346.PubMedCrossRef

24.

Rutkowski P, Nowecki Z, Nyckowski P, et al. Surgical treatment of patients with initially inoperable and/or metastatic gastrointestinal stromal tumors (GIST) during therapy with imatinib mesylate. J Surg Oncol 2006;93(4):304–311.PubMedCrossRef

25.

Blay JY, Le Cesne A, Ray-Coquard I, et al. Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group. J Clin Oncol 2007;25(9):1107–1113.PubMedCrossRef

26.

van der Zwan SM, DeMatteo RP. Gastrointestinal stromal tumor: 5 years later. Cancer 2005;104(9):1781–1788.PubMedCrossRef

Title: How I Do It: Surgical Management of Gastrointestinal Stromal Tumors
Authors: Chandrajit P. Raut
Stanley W. Ashley
Publication date: 01-09-2008
Publisher: Springer-Verlag
Published in: Journal of Gastrointestinal Surgery / Issue 9/2008
Print ISSN: 1091-255X
Electronic ISSN: 1873-4626
DOI: https://doi.org/10.1007/s11605-008-0501-3

Keynote webinar | Spotlight on medication adherence

Springer Medicine

How I Do It: Surgical Management of Gastrointestinal Stromal Tumors

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 9/2008

Is Vena Cava Resection Justified for Hydatid Liver Cyst?

The Effects of Vasopressors on Perfusion of Gastric Graft after Esophagectomy. An Experimental Study

Clostridium difficile Infection: A Surgical Disease in Evolution

Laparoscopic Bile Duct Reexploration for Retained Duct Stones

Hepatic and Splenic Hydatidosis Managed with Percutaneous Aspiration, Injection, and Reaspiration (PAIR) of the Hepatic Cyst and Laparoscopic Splenectomy

Is Vena Cava Resection Justified for Hydatid Liver Cyst. Reply